Authors : Azhar Sharif Fadlalmawla Alnaeem; Ahmed Siddig Akasha Hassan; Shiraz Jahalrsool Abdallah Jahalrsool; Hassan Mohammed Alhassan Mohammed; Esraa Omer Mustafa Hassan; Safaa Ibrahim Mohamed Ibrahim; Abdelaziz Hamza Alhaj Ibrahim; Braah Mohamed Omer Noureen

Volume/Issue : Volume 11 - 2026, Issue 3 - March

Google Scholar : https://tinyurl.com/f6u7zr4z

Scribd : https://tinyurl.com/m647242r

DOI : https://doi.org/10.38124/ijisrt/26mar782

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Background: Substance abuse poses significant health challenges, including hepatic and metabolic disruptions. "Ice Crystal" (Shabu), a methamphetamine-based drug, is widely abused and associated with severe physiological effects. Despite its prevalence, limited research exists on its impact on liver enzymes and ammonia levels in users.  Aim: This study aimed to evaluate the effects of Ice Crystal (Shabu) use on liver enzyme activity and ammonia levels and to examine correlations between substance usage patterns, demographics, and biochemical changes.  Methods: A cross-sectional study was conducted from March to April 2022, involving 50 Ice Crystal users (test group) and 50 non-users (control group). Blood samples were collected from all participants, and liver enzyme activity and ammonia levels were assessed using an automated chemistry analyzer. Statistical analyses were performed to compare biochemical markers between the groups and identify associations with variables such as age, gender, usage method, and quantity.  Results: The results revealed a significant elevation in liver enzyme activity and ammonia levels among the test group compared to the control group, with p-values of 0.005 and 0.001, respectively. Furthermore, positive correlations were observed between substance usage patterns (method and quantity), demographic factors (age and gender), and biochemical changes.  Conclusion: Ice Crystal (Shabu) use is significantly associated with elevated liver enzymes and ammonia levels, highlighting its potential to cause liver damage and metabolic disturbances. These findings emphasize the urgent need to raise awareness about the adverse health effects of methamphetamine abuse and advocate for preventive interventions to safeguard public health.

Keywords : Liver Enzymes, Ammonia, Methamphetamine Abusers, Khartoum State.

References :

1. U.S .Department of Justice  DEA, Diversion Control Division. National Forensic Laboratory Information System (NFLIS) 2015 AnnualReport.2016.
2. Chomchai C, ChomchaiS. Global patterns of methamphetamine use. Curr  OpinPsychiatry2015;28:269-74.
3. Panenka WJ, Procyshyn RM, LecomteT, etal. Methamphetamine use: A comprehensivereviewofmolecular,preclinicalandclinicalfindings.Drug AlcoholDepend2013;129:167-79.
4. Moszczynska A. Neurobiology and clinical manifestations of methamphetamineneurotoxicity.PsychiatricTimes2016Sept30.
5. Kish SJ .Pharmacologic mechanisms of crystal meth. Canadian Medical AssociationJournal2008;178:1679.
6. RadfarSR, Rawson RA. Current research on methamphetamine: epidemiology, medical and psychiatric effects, treatment, and harm reduction efforts.AddictHealth.2014Summer-Autumn;6(3-4):146-54.[PMC freearticle: PMC4354220] [PubMed:25984282]
7. J.R.Richards, E.B .Johnson, R. W. Stark, and R. W. Derlet, “Methamphetamine abuse and rhabdomyolysis in theED:a5-yearstudy,” TheAmericanJournalofEmergencyMedicine,vol.17,no.7,pp.681–685, 1999.
8. N.Shima,I.Miyawaki,K.Bandoetal.,“Influences of methamphetamine induced acute intoxication on urinary and plasma metabolic profiles in the rat,”Toxicology,vol.287,no.1–3,pp.29–37,2011.
9. A.L. Jones and K.J. Simpson,“ Review article: mechanisms and management of hepatotoxicity in ecstasy(MDMA)and amphetamine intoxications,”AlimentaryPharmacologyandTherapeutics,vol.13,no.2, pp.129–133,1999.
10. F.Carvalho,F.Remião,M.E.Soares,R.Catarino,G.Queiroz,andM.L. Bastos, “d-Amphetamine-induced hepatotoxicity: Possibie contribution of catecholamines and hyperthermia to the effect studied in isolated rat hepatocytes.
11. 11.Grisham, Charles M; Reginald H. Garrett (1999). Biochemistry. Philadelphia: Saunders College Pub.
12. Smith AL (Ed) (1997).Oxford dictionary of biochemistry and molecular biology. Oxford [Oxfordshire]:Oxford University Press. ISBN0-19-8547684.
13. Bishop, M.L., Fody, E.P., and Schoeff, L. (Eds.) Procedures, Correlations, 5^th ed. Philadelphia: Lippincott Williams & Wilkins.
14. Burtis, C.A., Ashwood, E.R., and Bruns, D.E. (Eds.) (2008). Tietz Fundamentals of Clinical Chemistry, 6^th ed. Philadelphia:Saunders.
15. Fersht, Alan (1985). Enzyme structure and mechanism. San Francisco: W.H. Freeman. pp.50-2–. ISBN0-7167-1615-1.
16. Zilva. JF and Panel P.R’ clinical chemistry in diagnosis’ 6^th  edition’ 1994.
17. Nalpas etal. 1984, Salaspuro 1987, Shethetal.1998, Prattand Kaplan 2000.
18. Bishop, M. L, Fody, E.B, Schoeff, L. E. The liver functionin :clinical chemistry‘ Techniques’ principle and Correlations‘ Lippincott Williams & Wilkins‘philadelphia‘USA’6^th ed.516-529’2010.
19. Shieh  J, Chen T, Lin C. Methamphetamine-associated hepatotoxicity: A review of pathophysiology and management. Liver Res. 2020; 4(2): 89–96.
20. Zhou Y, Ye F, Wang J. Methamphetamine-induced liver injury: Role of oxidative stress and inflammatory mediators. Clin Biochem. 2019; 65:15–22.
21. Watson R, Hartmann T, Tan X. Cholestasis and bile duct injury associated with substance abuse: A comprehensive review. Hepatol Int. 2021; 15(4):725–34.
22. Mulligan C, McKeown D, Randall D. Hyperammonemia and its implications in liver dysfunction: Methamphetamine-related insights. J Clin Med. 2022; 11(1):154.
23. Gorman A, Wong J, Yu S. Neurotoxicity of methamphetamine: Role of hepatic dysfunction and ammonia elevation. Neurochem Int. 2020; 132: 104614.
24. Halpin NW, Yamamoto BK. Methamphetamine-induced systemic hyperammonemia and its role in neurotoxicity. Journal of Neurochemistry. 2012; 121 (2): 253-263.
25. Al-Huseini, Huseini I, et al. Impact of methamphetamine substance abuse on liver function tests and lipid profile among addicts. J Clin Diagn Res. 2018;12(4).
26. Basu R, et al. Metabolic disturbances and hyperammonemia in substance use disorders: A clinical perspective. J Addict Dis. 2020;38(2):145-153.